CRNX vs. BHVN, RARE, PBH, INSM, HCM, BHC, XENE, IDYA, FOLD, and JANX
Should you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), Insmed (INSM), HUTCHMED (HCM), Bausch Health Companies (BHC), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.
Crinetics Pharmaceuticals currently has a consensus target price of $54.00, suggesting a potential upside of 14.41%. Biohaven has a consensus target price of $52.13, suggesting a potential upside of 28.10%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
In the previous week, Crinetics Pharmaceuticals and Crinetics Pharmaceuticals both had 4 articles in the media. Crinetics Pharmaceuticals' average media sentiment score of 0.95 beat Biohaven's score of 0.78 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
Biohaven received 235 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.18% of users gave Crinetics Pharmaceuticals an outperform vote while only 65.37% of users gave Biohaven an outperform vote.
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 16.0% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Crinetics Pharmaceuticals has higher earnings, but lower revenue than Biohaven. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Biohaven has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Crinetics Pharmaceuticals' return on equity of -52.93% beat Biohaven's return on equity.
Summary
Crinetics Pharmaceuticals beats Biohaven on 9 of the 17 factors compared between the two stocks.
Get Crinetics Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Crinetics Pharmaceuticals Competitors List
Related Companies and Tools
